CervoMed reported a net loss of $6.6 million for the second quarter of 2026, primarily reflecting the transition of its lead candidate neflamapimod toward Phase 3 readiness. The company bolstered its financial position with $20.5 million in gross proceeds from June equity financings, extending its operational runway into late 2027. Management is currently prioritizing a strategic partnership to advance neflamapimod for the treatment of dementia with Lewy bodies (DLB).
Key Highlights
- Cash and marketable securities reached $24.9 million as of June 30, 2026, compared to $20.9 million at year-end 2025.
- Grant revenue fell to zero for the quarter following the mid-2025 completion of the Phase 2b RewinD-LB clinical trial.
- Research and development expenses decreased 15.7% to $4.3 million due to lower clinical trial costs, partially offset by CMC-related activities for neflamapimod.